Trainer – Pharmaceutical Manufacturing
Permanent Position
Based in Greater London
Paying up to £36,000 annually + bonus + benefits
Are you experienced in delivering in-person, site based training?
Would you like to work for a reputable scientific organisation, in a role making a direct impact to company success through ensuring high quality training is delivered?
Are you an experienced synthetic chemist with a broad understanding of organic reactions?
Would you like to work for a leading drug discovery and development organisation?
by Tony Jones, CEO, One Nucleus
Being Asked to Do More With Less
The cascading challenge before the sector currently with respect to both companies and individuals working in it could be summarised as:
By Monalisa Breazu, Learning & Development Administrator
Back by popular demand after a superb GTR 2024.
What's this all about?
Cycle from Cambridge (with the ex-pro cyclist Yanto Critchlow-Barker 🚴♀️), Oxford or London meeting up at a pub in The Chilterns for a special biotech networking event in support of the children's medical research charity Action Medical Research.
KSBB-AFOB 2025 Conference marks the combined celebration of the 40th Anniversary Meeting and International Symposium of the Korean Society for Biotechnology and Bioengineering (KSBB) and the 17th Asian Congress on Biotechnology (ACB 2025). The conference will take place from September 23rd to 27th, 2025, in Incheon, Korea. Through the collaboration of KSBB and the Asian Federation of Biotechnology (AFOB), KSBB-AFOB Conference 2025 will serve as a premier venue for showcasing and exchanging the latest advancements in the rapidly growing field of biotechnology.
Building on the success of the 2024 summit, the 7th Exosome Based Therapeutic Development Summit returns with a refreshed program, with data-driven insights from those pioneering the field who are dedicated to the clinical translation and commercialization of exosome-based therapeutics across a broad range of disease indications.
Recent scientific developments, particularly in antibody engineering, have led to numerous innovations in cancer immunotherapy and one of the most promising innovations has been the development of bispecific antibodies, as bispecific drugs make huge waves in multiple myeloma and lymphoma, so much so that they threaten cell therapy in multiple myeloma.
Creative Biolabs has recently made upgrades to its CAR-T preclinical research, further enhancing the safety and functional evaluation of these therapies.
